Zydus Lifesciences has received exclusive marketing rights for CanAssist Breast- an innovative prognostic test for breast cancer patients. CanAssist Breast is a test to optimize treatment selection in early stage (I & II) hormone receptor positive, HER2 receptor negative type of breast cancer. It determines the patient’s risk of breast cancer recurrence and classifies patient as ‘low risk’ or ‘high risk’ using proprietary Artificial Intelligence/ Machine Learning methods. CanAssist Breast spares patients of physiological toxicity and is also patient-centric in terms of affordability as it is being made available at 80 percent lesser than the cost of global tests.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
